

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 23, 2004

-----  
(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

-----  
(Address of principal executive offices)

336-229-1127

-----  
(Registrant's telephone number, including area code)

Explanatory Note:

-----  
This 8-K/A is furnished to amend in full the Form 8-K furnished on February 24, 2004.

ITEM 9. Regulation FD Disclosure

On February 23, 2004, Laboratory Corporation of America -Registered Trademark- Holdings (LabCorp -Registered Trademark-) (NYSE:LH) announced that Myla Lai-Goldman, M.D., LabCorp executive vice president, chief scientific officer and medical director, is scheduled to speak at the Wachovia Securities Cancer Diagnostics Conference in New York, NY on February 24, 2004 at 9:00 a.m. Eastern Time. A live audio webcast of the presentation will be available via the Company web site at [www.labcorp.com](http://www.labcorp.com). A replay of the audio webcast will be available through March 24, 2004.

Exhibits:

99.1 Press release of the Company dated February 23, 2004.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Registrant)

By:/s/ BRADFORD T. SMITH

-----  
Bradford T. Smith  
Executive Vice President  
and Secretary

Date: February 23, 2004

EXHIBIT 99.1

Laboratory Corporation of America-Registered Trademark-Holdings  
358 South Main Street  
Burlington, NC 27215  
Telephone: (336) 584-5171

For Immediate Release

Contact: Pamela Sherry - (336) 436-4855  
Shareholder Direct: (800) LAB-0401  
Company Information: [www.LabCorp.com](http://www.LabCorp.com)

LABCORP-REGISTERED TRADEMARK-SCHEDULED TO PRESENT AT THE WACHOVIA  
SECURITIES CANCER DIAGNOSTICS CONFERENCE

Burlington, NC, February 23, 2004 - Laboratory Corporation of America - Registered Trademark- Holdings (LabCorp-Registered Trademark-) (NYSE: LH) today announced that Myla Lai-Goldman, M.D., LabCorp executive vice president, chief scientific officer and medical director, is scheduled to speak at the Wachovia Securities Cancer Diagnostics Conference in New York, NY on February 24, 2004 at 9:00 a.m. Eastern Time. A live audio webcast of the presentation will be available via the Company web site at [www.LabCorp.com](http://www.LabCorp.com). A replay of the audio webcast will be available through March 24, 2004.

About LabCorp

Laboratory Corporation of America -Registered Trademark- Holdings is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of \$2.9 billion in 2003, approximately 23,000 employees nationwide, and more than 220,000 clients, LabCorp offers over 4,400 clinical assays ranging from blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN; The Center for Esoteric Testing in Burlington, NC; and DIANON Systems, Inc. based in Stratford, CT. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our growing organization, visit our web site at: [www.LabCorp.com](http://www.LabCorp.com).

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2002 and will be included in the Company's form 10-K for the year ended December 31, 2003, when filed.